
Note sull'episodio
As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was yesterday, we’ve been able to squeeze them both in. The conversations this week are with Hansa Biopharma CEO Renée Aguiar-Lucander, about imlifidase for kidney transplant patients; Kyron.bio CEO Emilia McLaughlin, about glycosylation; and hydrogel-based drug delivery solutions company AmacaThera’s CEO, Mike Cooke.
Times:
03:56 Kyron.bio
19:14 AmacaThera
43:01 Hansa Biopharma
Hansa Biopharma
Hansa Biopharma AB is set for a busy year. In December, the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned ...
Parole chiave
biotech
biotechnology
kidney disease
AmacaThera
Kyron.bio
Hansa Biopharma
glycans
